Skip to main content

Posts

Showing posts from July, 2017

Zero-fat, clean, lab-made chicken on the way

Here is the good news for the non-vegetarians. Very hygienic, healthy and tasty laboratory-made chicken is coming soon into the Indian market. Research by biotechnology scientists proved that chicken can be made in the lab with same qualities, colour and taste as natural chicken. Moreover, the laboratory made chicken will be zero-fat. 
The first phase of the laboratory chicken (cultured or artificial chicken) research project was successfully completed at GITAM University. There are some satellite cells in human and animals. The cells are born automatically and healthy. These cells have unique feature that they can be developed or changed into any other cells in body. 

Continue reading


'Include local advice for drug trials in India'

Clinical trials done in India should be guided by local concerns and have a strong local participation, felt Roy Rampling, eminent neuro-oncologist and researcher. Delivering the Tata oration in clinical oncology on Friday, Rampling -a professor at the University of Glasgow -said he was surprised to find that clinical trials in India were often controlled entirely by foreign agencies and local investigators had no say in deciding their courses. "All trials are done in India should include local advise. It should be designed for the gain of the local community," said the Malta-born Rampling.
Describing India as the ideal venue for clinical trials, Rampling said the country was ready to take off in medical research... ...continue reading

Is ‘Right-to-try’ bill right?

The bill would exempt doctors and drug companies from liability of prescribing and supplying experimental drugs​.


image courtesy: Scienceblogs 'Right-to-try' is being debated fiercely in US as the American Congress is considering a bill on the topic. It is a practice allowing patients diagnosed with terminal illnesses to use drugs that are yet to be approved and are out of clinical trials, but have passed the first clinical test of safety. However, usage of even such drugs also requires Food & Drugs Administration (FDA) approval. The bill in the US Congress however, seeks to eliminate this FDA approval and monitoring of the process.The Trump administration has supported the bill and this is termed by many as a part of the administration's passion for deregulation. In all 33 states have already passed 'Right-to-try' laws. Efforts of Goldwater institute, a libertarian non-profit organisation that drafted the model law, have led to passing of the laws in the states…

India Contract Research Organization Market, is projected to grow at a CAGR of 20.4% and is expected to reach US$ 6,310.5 million by 2022

Market Research Future published a Statistic research report on India Contract Research Organization Market, from 2017 to 2022″ – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

​India Contract Research Organization Market, is projected to grow at a CAGR of 20.4% and is expected to reach US$ 6,310.5 million by 2022. In India contract research organization market, drug development/clinical trials accounted for the largest market share in 2016.
A Contract Research Organization (CRO) is a service association that offers help to the pharmaceutical business and offers an extensive variety of outsourced pharmaceutical research administrations to help in R&D system and in this way a basic tool for undertaking clinical trials in the present situation when high stakes are included in the drug discovery process. This industry likewise offers a safe choice of venture as the business is to a great extent recession-proof, with a critical upscale development.Get a sample cop…

BIOCAD’s rituximab biosimilar to receive MA soon in India

In August 2017, BIOCAD will receive permanent market authorization in India, which represents a strategic milestone for BIOCAD's international expansion.

The Central Drugs Standard Control Organization(CDSCO) has recommended Acellbia, the first rituximab biosimilarmade in Russia, for approval in India.

In August 2017, BIOCAD will receive permanent market authorization in India, which represents a strategic milestone for BIOCAD's international expansion.

Today, the Indian market for rituximab exceeds $40 m, with an annual growth of 8%. According to experts, this volume may reach $58 million in the next five years.

Meanwhile, India experiences low rituximab availability. Therefore, the Russian biosimilar marketed here will not only boost competition among the existing players, but will make this product available for larger numbers of patients with certain types of lymphomas and autoimmune disorders.

. . . ​Continue reading​